ARRHYTHMIAS in Adult Congenital Heart Disease
... ARRHYTHMIAS in Adult Congenital Heart Disease Annette Haynes RN, MS, CCRN Cardiology Clinical Nurse Specialist Stanford Hospital and Clinics Palo Alto, California INTRODUCTION Symptomatic arrhythmias occur with increasing frequency for adult congenital heart disease (ACHD) as they move through adole ...
... ARRHYTHMIAS in Adult Congenital Heart Disease Annette Haynes RN, MS, CCRN Cardiology Clinical Nurse Specialist Stanford Hospital and Clinics Palo Alto, California INTRODUCTION Symptomatic arrhythmias occur with increasing frequency for adult congenital heart disease (ACHD) as they move through adole ...
Update in Heart Failure
... Who should Consider an ICD? • Patients with weakend heart, New York Heart Association (NYHA) Class II and III heart failure, and measured left ventricular ejection fraction (LVEF) < 35% • Patients who meet all current requirements for a cardiac resynchronization therapy (CRT) device and have NYHA C ...
... Who should Consider an ICD? • Patients with weakend heart, New York Heart Association (NYHA) Class II and III heart failure, and measured left ventricular ejection fraction (LVEF) < 35% • Patients who meet all current requirements for a cardiac resynchronization therapy (CRT) device and have NYHA C ...
Cardiac Conducting System AND Cardiac cycle
... i. Fibrous skeletal separates atria from ventricle 2. AV node: a. Floor of right atrium b. Near opening of coronary sinus c. From AV node to bundle of His( Left and right bundle ...
... i. Fibrous skeletal separates atria from ventricle 2. AV node: a. Floor of right atrium b. Near opening of coronary sinus c. From AV node to bundle of His( Left and right bundle ...
MANAGEMENT OF CHRONIC HEART FAILURE
... • Some of these underlying causes are surgically correctable, and in some either the underlying disease (e.g. hyperthyroidism;), or an aggravating factor such as anaemia or atrial fibrillation, is treatable with drugs. ...
... • Some of these underlying causes are surgically correctable, and in some either the underlying disease (e.g. hyperthyroidism;), or an aggravating factor such as anaemia or atrial fibrillation, is treatable with drugs. ...
Perindopril preserves left ventricular function in X
... basement membrane. Its absence is responsible for membrane fragility, loss of transductional force and, ultimately, myocyte necrosis promoted by mechanical stress.17,18 Thus, afterload reduction by perindopril may be a key factor in our study, which included children with DMD who were, on an average ...
... basement membrane. Its absence is responsible for membrane fragility, loss of transductional force and, ultimately, myocyte necrosis promoted by mechanical stress.17,18 Thus, afterload reduction by perindopril may be a key factor in our study, which included children with DMD who were, on an average ...
Paracor HeartNet cardiac restraint device
... Medical therapy for heart failure includes the use of drugs such as β-blockers and angiotensin-converting enzyme inhibitors, which can attenuate neurohormonal changes and LV remodelling. Surgery (such as revascularisation surgery or mitral valve repair when there is a correctable problem causing the ...
... Medical therapy for heart failure includes the use of drugs such as β-blockers and angiotensin-converting enzyme inhibitors, which can attenuate neurohormonal changes and LV remodelling. Surgery (such as revascularisation surgery or mitral valve repair when there is a correctable problem causing the ...
The history of cardiac diagnosis
... • 5th C BC Chinese physician Pein Ts Lo; pulse theory. Separate pulses connected to various organs eg liver and spleen ...
... • 5th C BC Chinese physician Pein Ts Lo; pulse theory. Separate pulses connected to various organs eg liver and spleen ...
Effect of Empagliflozin on Left Ventricular Mass and
... of power in this study remains possible. The metabolic/myocardial fuel-supply hypothesis postulates that empagliflozin, through increased ketone body production such as b-hydroxybutarate, may provide an alternative and potentially more efficient source of myocardial adenosine triphosphate (5). Changes ...
... of power in this study remains possible. The metabolic/myocardial fuel-supply hypothesis postulates that empagliflozin, through increased ketone body production such as b-hydroxybutarate, may provide an alternative and potentially more efficient source of myocardial adenosine triphosphate (5). Changes ...
deperalta_f
... – Minimize unnecessary visits and admissions – Provide care in the least intensive setting ...
... – Minimize unnecessary visits and admissions – Provide care in the least intensive setting ...
heart failure
... It is also most helpful in patients with a dilated heart & third heart sound. It is usually given after ACE inhibitors. When symptoms are mild, slow loading (digitalization) is safer and just as effective as the rapid method. ...
... It is also most helpful in patients with a dilated heart & third heart sound. It is usually given after ACE inhibitors. When symptoms are mild, slow loading (digitalization) is safer and just as effective as the rapid method. ...
PDF Handout
... of cancer. In the US annually, HF is the principal cause of death in >65,000 individuals, a contributing factor in over 300,000 deaths, and over 900,000 persons have a new diagnosis of HF. It has been estimated that at least 60,000 of these persons could benefit from heart transplantation or lon ...
... of cancer. In the US annually, HF is the principal cause of death in >65,000 individuals, a contributing factor in over 300,000 deaths, and over 900,000 persons have a new diagnosis of HF. It has been estimated that at least 60,000 of these persons could benefit from heart transplantation or lon ...
Provider Bills:
... May have other applications Inappropriate use risks exposure to substantial radiation Currently still in clinical trials, but anticipate widespread use ...
... May have other applications Inappropriate use risks exposure to substantial radiation Currently still in clinical trials, but anticipate widespread use ...
Treatment of CHF
... Elimination of alcohol in cardiomyopathy; moderation in other conditions. Aerobic exercise (mentioned above); cardiac rehabilitation where indicated. Smoking cessation. ...
... Elimination of alcohol in cardiomyopathy; moderation in other conditions. Aerobic exercise (mentioned above); cardiac rehabilitation where indicated. Smoking cessation. ...
Needs to Know - Preventive Cardiovascular Nurses Association
... as many medications • Yet are frequently forgotten or deemed to be not necessary or not beneficial • Concordance of trials have shown improvement in important morbidity and mortality outcomes ...
... as many medications • Yet are frequently forgotten or deemed to be not necessary or not beneficial • Concordance of trials have shown improvement in important morbidity and mortality outcomes ...
S0735109705017687_mmc1
... IA: An early invasive strategy in patients with unstable angina/non–ST-segment myocardial infarction without serious comorbidity with high-risk indicators: (a) recurrent angina/ischemia at rest or with low-level activities despite intensive anti-ischemic therapy; (b) elevated TnT or TnI; (c) new or ...
... IA: An early invasive strategy in patients with unstable angina/non–ST-segment myocardial infarction without serious comorbidity with high-risk indicators: (a) recurrent angina/ischemia at rest or with low-level activities despite intensive anti-ischemic therapy; (b) elevated TnT or TnI; (c) new or ...
Pediatric Cardiac Rhythm Analysis for the Non
... of the heart. Explain cardiac electrical conduction system and its relationship to the cardiac cycle. Identify the common arrhythmias in infants and children. Recognize the nursing assessments and actions related to the arrhythmias. ...
... of the heart. Explain cardiac electrical conduction system and its relationship to the cardiac cycle. Identify the common arrhythmias in infants and children. Recognize the nursing assessments and actions related to the arrhythmias. ...
Statins in Preparation for Chemotherapy
... The strengths of these data include their thorough observational nature, similar to a practical registry, with an excellent description of cardiovascular risk factors. Previously, there has not been a detailed assessment of cardiac risk factors and comorbidities in a cancer population, and this info ...
... The strengths of these data include their thorough observational nature, similar to a practical registry, with an excellent description of cardiovascular risk factors. Previously, there has not been a detailed assessment of cardiac risk factors and comorbidities in a cancer population, and this info ...
ECG NOTES
... • Rate is usually normal and may be regular except when PVC occurs. PVC may occur alone at regular intervals (bigeminy, trigeminy) or in clusters (salvos). If 6 or more PVCs occur in 1 minute, the heart is becoming very irritable and ventricular tachycardia can begin at any time. ...
... • Rate is usually normal and may be regular except when PVC occurs. PVC may occur alone at regular intervals (bigeminy, trigeminy) or in clusters (salvos). If 6 or more PVCs occur in 1 minute, the heart is becoming very irritable and ventricular tachycardia can begin at any time. ...
Heart Anatomy
... • Have unstable resting potentials called pacemaker potentials • Use calcium influx (rather than sodium) for rising phase of the action potential ...
... • Have unstable resting potentials called pacemaker potentials • Use calcium influx (rather than sodium) for rising phase of the action potential ...
Heart Failure
... ang. II . These agents also diminish the rate of bradykinin inactivation. [Vasodilation occurs as a result of the combined effects of lower vasoconstriction caused by diminished levels of ang. II and the potent vasodilating effect of increased bradykinin.] 2- By reducing circulating ang II levels, A ...
... ang. II . These agents also diminish the rate of bradykinin inactivation. [Vasodilation occurs as a result of the combined effects of lower vasoconstriction caused by diminished levels of ang. II and the potent vasodilating effect of increased bradykinin.] 2- By reducing circulating ang II levels, A ...
PowerPoint - New Page 1
... pump sufficient blood to organs to… furnish oxygen/substrates and remove metabolites… thereby maintaining ‘steady-state’ (homeostasis) ...
... pump sufficient blood to organs to… furnish oxygen/substrates and remove metabolites… thereby maintaining ‘steady-state’ (homeostasis) ...
Common Arrhythmias in Dogs and Cats
... and their job is to squeeze extra blood into the lower pumping chambers (the ventricles). When the atria fibrillate, the ventricle lose this extra “kick” from the atria, and this will lead to less filling of the ventricles, and less forceful of a contraction. Typically the heart rate is extremely fa ...
... and their job is to squeeze extra blood into the lower pumping chambers (the ventricles). When the atria fibrillate, the ventricle lose this extra “kick” from the atria, and this will lead to less filling of the ventricles, and less forceful of a contraction. Typically the heart rate is extremely fa ...
Chest Pain
... “There’s an elephant sitting on my chest” Squeezing “Tight band around my chest” Pain through to the back ...
... “There’s an elephant sitting on my chest” Squeezing “Tight band around my chest” Pain through to the back ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.